Literature DB >> 12642462

Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption.

Debbie Tam1, Rommel G Tirona, K Sandy Pang.   

Abstract

Recently, a physiologically-based, segregated flow model that incorporates separate intestinal tissue and flow to both a nonabsorptive and an absorptive outermost layer (enterocytes) was shown to better describe the observations on route-dependent morphine glucuronidation in the rat small intestine than a traditional physiologically-based model. These theoretical models were expanded, as the segmental segregated flow model and the segmental traditional model, to view the intestine as three segments of equal lengths receiving equal flows to accommodate heterogeneities in segmental transporter and metabolic functions. The influence of heterogeneity in absorptive, exsorptive, and metabolic functions on drug clearance, bioavailability (F), and metabolite formation after intravenous and oral dosing was examined for the intestine when the tissue was the only organ of removal. Simulations were performed for first-order conditions, when drug partitioned readily (flow-limited distribution) or less readily (membrane-limited distribution) into intestinal tissue, and for different gastrointestinal transit times. The intestinal clearance was found to be inversely related to the rate constant for absorption of a drug that was subjected to secretion and was positively correlated with the metabolic and secretory intrinsic clearances. F was positively correlated with the absorption rate constant but was inversely related to the metabolic and secretory intrinsic clearances. The gastrointestinal transit time decreased metabolite formation, increased clearance, and decreased F. The simulations further showed that a descending metabolic intrinsic clearance yielded a lower F and an ascending segmental distribution of metabolic intrinsic clearance yielded a higher F.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642462     DOI: 10.1124/dmd.31.4.373

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

2.  The importance of villous physiology and morphology in mechanistic physiologically-based pharmacokinetic models.

Authors:  Emile P Chen; Guoying Tai; Harma Ellens
Journal:  Pharm Res       Date:  2013-08-30       Impact factor: 4.200

Review 3.  Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts.

Authors:  K Sandy Pang; Michael Weiss; Panos Macheras
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

Review 4.  Mechanistic approaches to predicting oral drug absorption.

Authors:  Weili Huang; Sau Lawrence Lee; Lawrence X Yu
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

Review 5.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

Review 6.  Bioavailability and bioequivalence: focus on physiological factors and variability.

Authors:  Vangelis Karalis; Panos Macheras; Achiel Van Peer; Vinod P Shah
Journal:  Pharm Res       Date:  2008-06-13       Impact factor: 4.200

7.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

Review 8.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

9.  The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.

Authors:  Arik Dahan; Hairat Sabit; Gordon L Amidon
Journal:  AAPS J       Date:  2009-03-25       Impact factor: 4.009

Review 10.  Gastrointestinal microphysiological systems.

Authors:  Sarah E Blutt; James R Broughman; Winnie Zou; Xi-Lei Zeng; Umesh C Karandikar; Julie In; Nicholas C Zachos; Olga Kovbasnjuk; Mark Donowitz; Mary K Estes
Journal:  Exp Biol Med (Maywood)       Date:  2017-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.